BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang X, El-Serag HB, Thrift AP. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes Control 2021;32:317-25. [PMID: 33394207 DOI: 10.1007/s10552-020-01386-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Yen Y, Kee K, Li W, Liu Y, Wang C, Hu T, Tsai M, Kuo Y, Lin C. Causes of Death among Patients with Hepatocellular Carcinoma According to Chronic Liver Disease Etiology. Cancers 2023;15:1687. [DOI: 10.3390/cancers15061687] [Reference Citation Analysis]
2 Thrift AP, Kanwal F, Liu Y, Khaderi S, Singal AG, Marrero JA, Loo N, Asrani SK, Luster M, Al-Sarraj A, Ning J, Tsavachidis S, Gu X, Amos CI, El-Serag HB. Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One 2023;18:e0282309. [PMID: 36854015 DOI: 10.1371/journal.pone.0282309] [Reference Citation Analysis]
3 Shahini E, Pasculli G, Solimando AG, Tiribelli C, Cozzolongo R, Giannelli G. Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review. Int J Mol Sci 2023;24. [PMID: 36901717 DOI: 10.3390/ijms24054286] [Reference Citation Analysis]
4 Parikh ND, Tayob N, Singal AG. Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era? J Hepatol 2023;78:207-16. [PMID: 36089157 DOI: 10.1016/j.jhep.2022.08.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kim EJ, Ganga A, Lee JY, Zawadzki RS, Adriance W, Wang R, Cholankeril G, Somasundar PS. Disparities in hepatocellular carcinoma survival by Medicaid-status: A national population-based risk analysis. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.12.001] [Reference Citation Analysis]
6 Zhang H, Du X, Dong H, Xu W, Zhou P, Liu S, Qing X, Zhang Y, Yang M, Zhang Y. Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database. BMC Gastroenterol 2022;22:348. [PMID: 35854221 DOI: 10.1186/s12876-022-02424-5] [Reference Citation Analysis]
7 Oluyomi AO, Mohammadi KA, El-Serag HB, Thrift AP. Mediating Effects of Neighborhood-Level Socioeconomic Deprivation on the Association Between Race/Ethnicity and Advanced Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev 2022;31:1402-9. [PMID: 35314860 DOI: 10.1158/1055-9965.EPI-21-1396] [Reference Citation Analysis]
8 Ju MR, Polanco PM. ASO Author Reflections: Disparities in Utilization of Curative-Intent Therapy for Veterans with Early-Stage HCC. Ann Surg Oncol. [DOI: 10.1245/s10434-022-11956-9] [Reference Citation Analysis]
9 Akada K, Koyama N, Miura Y, Aoshima K. Nationwide database analysis of insomnia, depression, and sleeping pill prescriptions in hepatocellular carcinoma patients. Curr Med Res Opin 2022;:1-28. [PMID: 35608320 DOI: 10.1080/03007995.2022.2081451] [Reference Citation Analysis]
10 Adeniji N, Dhanasekaran R. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatol Commun 2021. [PMID: 34533885 DOI: 10.1002/hep4.1823] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
11 Ocker M, Mayr C, Kiesslich T, Stintzing S, Neureiter D. Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers (Basel) 2021;13:1558. [PMID: 33805268 DOI: 10.3390/cancers13071558] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]